A multi-arm Phase I study which investigated both drugs in combination with either irinotecan or the MEK inhibitor PD-0325901 reported preliminary evidence of activity of gedatolisib plus the MEK inhibitor PD-0325901 in 3 ovarian cancer patients (all partial responses) out of 5 tested28. The gene discussed is MAP2K7; the disease is ovarian carcinoma.